Status:
UNKNOWN
Biomarker-based Prognostic Assessment
Lead Sponsor:
Qilu Hospital of Shandong University
Collaborating Sponsors:
Peking University Third Hospital
Chinese PLA General Hospital Hospital
Conditions:
Acute Coronary Syndrome
Stable Angina
Eligibility:
All Genders
18-85 years
Brief Summary
Coronary artery disease (including stable angina and acute coronary disease) remains the leading mortality and morbidity worldwide. Improvement in biomarker, imaging research have led to new predictor...
Detailed Description
Patients enrolled in Qilu Hospital of Shandong University (Jinan, China), Chinese PLA General Hospital Hospital (Beijing, China) and Peking University First Hospital (Beijing, China) are designed as t...
Eligibility Criteria
Inclusion
- Hospitalized patients with the diagnosis of any type of coronary artery disease (stable angina, unstable angina, non ST-segment elevation myocardial infarction or ST-segment elevation myocardial infarction)
- Age ≥18 years of age and \<85 years of age
- Patient or guardian provided informed written consent
Exclusion
- Prior surgery (cardiac or non-cardiac), trauma or clinically evident coagulopathic bleeding (e.g. gastrointestinal, genitourinary, et al)
- Patient with non-cardiac co-morbidities with life expectancy less than 12 months
- Patients unwilling or unable to comply with all clinical follow-up schedules at 30 days, 6 months and 12 months after discharge
Key Trial Info
Start Date :
November 9 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2020
Estimated Enrollment :
10000 Patients enrolled
Trial Details
Trial ID
NCT04044066
Start Date
November 9 2017
End Date
December 31 2020
Last Update
July 7 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Qilu Hospital, Shandong University
Jinan, Shandong, China, 250012